NEW YORK, Nov. 06, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is investigating potential claims against Cantaloupe, Inc. (NASDAQ: CTLP, OTCMKTS: CTLPP), EyePoint Pharmaceuticals , Inc (NASDAQ: EYPT), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and F45 Training Holdings, Inc. (NYSE: FXLV). Our investigations address whether these companies have violated federal securities laws and/or engaged in other illegal business practices. For more information on each case, see the link provided.

Cantaloupe, Inc. (NASDAQ:CTLP,OTCMKTS:CTLPP)

On September 28, 2022, the company issued a report stating, “Based on the progress made to date in evaluating the effectiveness of internal controls for financial reporting, the company currently expects to report three material weaknesses in its internal control framework and design.” , the implementation and operational effectiveness of general information technology controls in the areas of user access, change management and segregation of duties within various systems that support the company’s accounting and reporting processes, the design, implementation and operational effectiveness of controls over revenue and related accounts and risk assessment and monitoring activities with a view to the timely identification and assessment of control deficiencies.”

On the news, Cantaloupe stock fell $0.17 per share, or 4.6%, to close at $3.47 per share on September 29, 2022.

For more information on the Cantaloupe investigation, visit: https://bespc.com/cases/CTLP

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

On August 30, 2022, after the market close, EyePoint announced that it had received a subpoena from the United States Attorney for the District of Massachusetts. The subpoena requested documents covering the company’s sales practices for its post-surgical inflammation treatment DEXYCU.

As a result of this news, EyePoint stock fell $0.21…